Robert Dreicer, MD
Medical Oncology · Charlottesville, VANPI 1871557595
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $201,459 of the $296,311 with a category attached, or 68.0%. 21 manufacturers reported payments, led by Pfizer at 24.4% of the total. Among medical oncology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 253 payments — averaging $1171.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$72K
- Merck$71K
- Bayer$22K
- Eisai Inc.$20K
- Orion Corporation$14K
- Seagen Inc.$13K
- plus $84K from 15 others
Across 420 payments — averaging $12,238 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exelixis Inc.$2.4M
- Novartis$1.5M
- Seagen Inc.$277K
- Gilead$156K
- Regeneron$151K
- Pfizer$137K
- plus $553K from 13 others
What the payments were for
- Consulting fees$201,45968%
- Speaking & faculty fees$69,68424%
- Travel & lodging$21,2747%
- Food & beverage$3,7441%
- Education$1500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 50 | $72,337 |
| Merck | 62 | $70,803 |
| Bayer | 11 | $21,853 |
| Eisai Inc. | 22 | $20,149 |
| Orion Corporation | 3 | $14,384 |
| Seagen Inc. | 23 | $12,681 |
| Sanofi | 7 | $11,616 |
| Astellas Pharma US Inc | 13 | $9,516 |
| Urogen Pharma, Inc. | 7 | $9,087 |
| AstraZeneca | 9 | $8,873 |
| Exelixis Inc. | 5 | $8,125 |
| Genentech, Inc. | 8 | $7,504 |
| Advanced Accelerator Applications | 4 | $6,403 |
| Gilead | 6 | $6,092 |
| Janssen Scientific Affairs, LLC | 6 | $5,114 |
| F. Hoffmann-la Roche AG | 7 | $4,909 |
| EMD Serono, Inc. | 4 | $3,017 |
| ADC Therapeutics America, Inc. | 2 | $1,500 |
| Astellas Pharma Global Development | 2 | $1,365 |
| Johnson & Johnson | 1 | $660 |
| Immunomedics, Inc. | 1 | $325 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$296,311 in reported general payments places this provider in the 95th percentile of 95 medical oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 42 | $53,629 |
| Prednisone | 31 | $298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $5,114 | $53,62942 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 95 medical oncology providers in Virginia.
Other medical oncology in Charlottesville
- Ryan GentzlerCharlottesville$62K
- Matthew ReilleyCharlottesville$37K
- Enrica MarchiCharlottesville$30K
- Richard HallCharlottesville$29K
- Paul ViscuseCharlottesville$12K
- Ludimila CavalcanteCharlottesville$7K
- William SkeltonCharlottesville$6K
- Paul KunkCharlottesville$4K
- John WagnerCharlottesville$1K
- Patrick DillonCharlottesville$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.